AutomedicationFrancoV1, Main, Exploration, bibRecord, 000542

Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.

Identifieur interne : 000542 ( Main/Exploration ); précédent : 000541; suivant : 000543

Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.

Auteurs : Yves Michiels [Suisse] ; Olivier Bugnon [Suisse] ; Annie Chicoye [France] ; Sylvie Dejager [France] ; Christine Moisan [France] ; François-André Allaert [France] ; Catherine Hunault [France] ; Laura Romengas [France] ; Hubert Méchin [France] ; Bruno Vergès [France]

Source :

Advances in therapy [ 1865-8652 ] ; 2019.

RBID : pubmed:31049873

Descripteurs français

KwdFr :
- Adhésion au traitement médicamenteux (statistiques et données numériques), Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse de regroupements (MeSH), Diabète de type 2 (traitement médicamenteux), Enquêtes et questionnaires (MeSH), Femelle (MeSH), France (MeSH), Humains (MeSH), Hyperglycémie (traitement médicamenteux), Hypoglycémiants (usage thérapeutique), Mâle (MeSH), Pharmaciens (psychologie), Relations médecin-patient (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Éducation du patient comme sujet (méthodes), Études de suivi (MeSH).
MESH :
- méthodes : Éducation du patient comme sujet.
- psychologie : Pharmaciens.
- statistiques et données numériques : Adhésion au traitement médicamenteux.
- traitement médicamenteux : Diabète de type 2, Hyperglycémie.
- usage thérapeutique : Hypoglycémiants.
- Adulte, Adulte d'âge moyen, Analyse de regroupements, Enquêtes et questionnaires, Femelle, France, Humains, Mâle, Relations médecin-patient, Sujet âgé, Sujet âgé de 80 ans ou plus, Études de suivi.
Wicri :
- geographic : France.

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Cluster Analysis (MeSH), Diabetes Mellitus, Type 2 (drug therapy), Female (MeSH), Follow-Up Studies (MeSH), France (MeSH), Humans (MeSH), Hyperglycemia (drug therapy), Hypoglycemic Agents (therapeutic use), Male (MeSH), Medication Adherence (statistics & numerical data), Middle Aged (MeSH), Patient Education as Topic (methods), Pharmacists (psychology), Physician-Patient Relations (MeSH), Surveys and Questionnaires (MeSH).
MESH :
- chemical , therapeutic use : Hypoglycemic Agents.
- geographic : France.
- drug therapy : Diabetes Mellitus, Type 2, Hyperglycemia.
- methods : Patient Education as Topic.
- psychology : Pharmacists.
- statistics & numerical data : Medication Adherence.
- Adult, Aged, Aged, 80 and over, Cluster Analysis, Female, Follow-Up Studies, Humans, Male, Middle Aged, Physician-Patient Relations, Surveys and Questionnaires.

Abstract

INTRODUCTION

Low-quality communication between patients and care providers and limited patient knowledge of the disease and the therapy are important factors associated with poor glycemic control in patients with type 2 diabetes. We conducted a multicenter study to determine whether structured and tailored information delivered by pharmacists to type 2 diabetic patients could improve patient treatment adherence, hemoglobin A1c (HbA1c) levels and knowledge about diabetes.

METHODS

One hundred seventy-four pharmacies were randomized to deliver an educational program on diet, drug treatment, disease and complications during three 30-min interviews over a 6-month period, or to provide no intervention, to type 2 diabetic patients treated with oral antidiabetic agents. Medication adherence was assessed by measuring the medication possession ratio and diabetes control by collecting HbA1c values. Levels of patient treatment self-management and disease knowledge were assessed using self-questionnaires.

RESULTS

Three hundred seventy-seven patients were analyzed. The medication possession ratio, already very high at baseline in the intervention (94.8%) and control (92.3%) groups, did not vary significantly after 6 months with no difference between the two groups. Significant decreases in HbA1c were observed in both groups at 6 months (p < 0.001) and 12 months (p < 0.01), with significantly greater changes from baseline in the intervention group than in the control group at 6 months (- 0.5% vs. - 0.2%, p = 0.0047) and 12 months (- 0.6% vs. - 0.2%, p = 0.0057). Patients in the intervention group showed greater improvement in their ability to self-manage treatment (+ 4.86 vs. + 1.58, p = 0.0014) and in the extent of their knowledge about diabetes (+ 0.6 vs. + 0.2, p < 0.01) at 6 months versus baseline compared with the control group.

CONCLUSION

Tailored information provided by the pharmacist to patients with type 2 diabetes did not significantly improve the already high adherence rates, but was associated with a significant decrease in HbA1c and an improvement of patient knowledge about diabetes.

TRIAL REGISTRATION

ISRCTN33776525.

FUNDING

MSD France.

DOI: 10.1007/s12325-019-00957-y
PubMed: 31049873
PubMed Central: PMC6824455

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000503
to stream Main, to step Curation: 000503

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.</title>
<author><name sortKey="Michiels, Yves" sort="Michiels, Yves" uniqKey="Michiels Y" first="Yves" last="Michiels">Yves Michiels</name>
<affiliation wicri:level="4"><nlm:affiliation>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
<orgName type="university">Université de Genève</orgName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bugnon, Olivier" sort="Bugnon, Olivier" uniqKey="Bugnon O" first="Olivier" last="Bugnon">Olivier Bugnon</name>
<affiliation wicri:level="4"><nlm:affiliation>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
<orgName type="university">Université de Genève</orgName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chicoye, Annie" sort="Chicoye, Annie" uniqKey="Chicoye A" first="Annie" last="Chicoye">Annie Chicoye</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut d'Études Politiques de Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut d'Études Politiques de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dejager, Sylvie" sort="Dejager, Sylvie" uniqKey="Dejager S" first="Sylvie" last="Dejager">Sylvie Dejager</name>
<affiliation wicri:level="1"><nlm:affiliation>MSD France, Courbevoie, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>MSD France, Courbevoie</wicri:regionArea>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Courbevoie</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moisan, Christine" sort="Moisan, Christine" uniqKey="Moisan C" first="Christine" last="Moisan">Christine Moisan</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Diabetology, Pitie Salpetrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Diabetology, Pitie Salpetrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allaert, Francois Andre" sort="Allaert, Francois Andre" uniqKey="Allaert F" first="François-André" last="Allaert">François-André Allaert</name>
<affiliation wicri:level="3"><nlm:affiliation>Evaluation Chair BSB-Cenbiotech, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Evaluation Chair BSB-Cenbiotech, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hunault, Catherine" sort="Hunault, Catherine" uniqKey="Hunault C" first="Catherine" last="Hunault">Catherine Hunault</name>
<affiliation wicri:level="1"><nlm:affiliation>MSD France, Courbevoie, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>MSD France, Courbevoie</wicri:regionArea>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Courbevoie</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Romengas, Laura" sort="Romengas, Laura" uniqKey="Romengas L" first="Laura" last="Romengas">Laura Romengas</name>
<affiliation wicri:level="3"><nlm:affiliation>Observia Group, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Observia Group, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mechin, Hubert" sort="Mechin, Hubert" uniqKey="Mechin H" first="Hubert" last="Méchin">Hubert Méchin</name>
<affiliation wicri:level="3"><nlm:affiliation>Observia Group, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Observia Group, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Verges, Bruno" sort="Verges, Bruno" uniqKey="Verges B" first="Bruno" last="Vergès">Bruno Vergès</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Endocrinology, Diabetology and Metabolic Diseases, CHU Dijon, Dijon, France. bruno.verges@chu-dijon.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Endocrinology, Diabetology and Metabolic Diseases, CHU Dijon, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31049873</idno>
<idno type="pmid">31049873</idno>
<idno type="doi">10.1007/s12325-019-00957-y</idno>
<idno type="pmc">PMC6824455</idno>
<idno type="wicri:Area/Main/Corpus">000503</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000503</idno>
<idno type="wicri:Area/Main/Curation">000503</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000503</idno>
<idno type="wicri:Area/Main/Exploration">000503</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.</title>
<author><name sortKey="Michiels, Yves" sort="Michiels, Yves" uniqKey="Michiels Y" first="Yves" last="Michiels">Yves Michiels</name>
<affiliation wicri:level="4"><nlm:affiliation>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
<orgName type="university">Université de Genève</orgName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bugnon, Olivier" sort="Bugnon, Olivier" uniqKey="Bugnon O" first="Olivier" last="Bugnon">Olivier Bugnon</name>
<affiliation wicri:level="4"><nlm:affiliation>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
<orgName type="university">Université de Genève</orgName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne</wicri:regionArea>
<placeName><settlement type="city">Lausanne</settlement>
<region nuts="3" type="region">Canton de Vaud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chicoye, Annie" sort="Chicoye, Annie" uniqKey="Chicoye A" first="Annie" last="Chicoye">Annie Chicoye</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut d'Études Politiques de Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut d'Études Politiques de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dejager, Sylvie" sort="Dejager, Sylvie" uniqKey="Dejager S" first="Sylvie" last="Dejager">Sylvie Dejager</name>
<affiliation wicri:level="1"><nlm:affiliation>MSD France, Courbevoie, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>MSD France, Courbevoie</wicri:regionArea>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Courbevoie</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moisan, Christine" sort="Moisan, Christine" uniqKey="Moisan C" first="Christine" last="Moisan">Christine Moisan</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Diabetology, Pitie Salpetrière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Diabetology, Pitie Salpetrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allaert, Francois Andre" sort="Allaert, Francois Andre" uniqKey="Allaert F" first="François-André" last="Allaert">François-André Allaert</name>
<affiliation wicri:level="3"><nlm:affiliation>Evaluation Chair BSB-Cenbiotech, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Evaluation Chair BSB-Cenbiotech, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hunault, Catherine" sort="Hunault, Catherine" uniqKey="Hunault C" first="Catherine" last="Hunault">Catherine Hunault</name>
<affiliation wicri:level="1"><nlm:affiliation>MSD France, Courbevoie, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>MSD France, Courbevoie</wicri:regionArea>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Courbevoie</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Romengas, Laura" sort="Romengas, Laura" uniqKey="Romengas L" first="Laura" last="Romengas">Laura Romengas</name>
<affiliation wicri:level="3"><nlm:affiliation>Observia Group, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Observia Group, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mechin, Hubert" sort="Mechin, Hubert" uniqKey="Mechin H" first="Hubert" last="Méchin">Hubert Méchin</name>
<affiliation wicri:level="3"><nlm:affiliation>Observia Group, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Observia Group, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Verges, Bruno" sort="Verges, Bruno" uniqKey="Verges B" first="Bruno" last="Vergès">Bruno Vergès</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Endocrinology, Diabetology and Metabolic Diseases, CHU Dijon, Dijon, France. bruno.verges@chu-dijon.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Endocrinology, Diabetology and Metabolic Diseases, CHU Dijon, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Advances in therapy</title>
<idno type="eISSN">1865-8652</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Cluster Analysis (MeSH)</term>
<term>Diabetes Mellitus, Type 2 (drug therapy)</term>
<term>Female (MeSH)</term>
<term>Follow-Up Studies (MeSH)</term>
<term>France (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hyperglycemia (drug therapy)</term>
<term>Hypoglycemic Agents (therapeutic use)</term>
<term>Male (MeSH)</term>
<term>Medication Adherence (statistics & numerical data)</term>
<term>Middle Aged (MeSH)</term>
<term>Patient Education as Topic (methods)</term>
<term>Pharmacists (psychology)</term>
<term>Physician-Patient Relations (MeSH)</term>
<term>Surveys and Questionnaires (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adhésion au traitement médicamenteux (statistiques et données numériques)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Analyse de regroupements (MeSH)</term>
<term>Diabète de type 2 (traitement médicamenteux)</term>
<term>Enquêtes et questionnaires (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>France (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hyperglycémie (traitement médicamenteux)</term>
<term>Hypoglycémiants (usage thérapeutique)</term>
<term>Mâle (MeSH)</term>
<term>Pharmaciens (psychologie)</term>
<term>Relations médecin-patient (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Éducation du patient comme sujet (méthodes)</term>
<term>Études de suivi (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hypoglycemic Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
<term>Hyperglycemia</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Patient Education as Topic</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Éducation du patient comme sujet</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Pharmaciens</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Pharmacists</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Medication Adherence</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Adhésion au traitement médicamenteux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term>
<term>Hyperglycémie</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hypoglycémiants</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cluster Analysis</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Physician-Patient Relations</term>
<term>Surveys and Questionnaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de regroupements</term>
<term>Enquêtes et questionnaires</term>
<term>Femelle</term>
<term>France</term>
<term>Humains</term>
<term>Mâle</term>
<term>Relations médecin-patient</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b>
</p>
<p>Low-quality communication between patients and care providers and limited patient knowledge of the disease and the therapy are important factors associated with poor glycemic control in patients with type 2 diabetes. We conducted a multicenter study to determine whether structured and tailored information delivered by pharmacists to type 2 diabetic patients could improve patient treatment adherence, hemoglobin A1c (HbA1c) levels and knowledge about diabetes.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>One hundred seventy-four pharmacies were randomized to deliver an educational program on diet, drug treatment, disease and complications during three 30-min interviews over a 6-month period, or to provide no intervention, to type 2 diabetic patients treated with oral antidiabetic agents. Medication adherence was assessed by measuring the medication possession ratio and diabetes control by collecting HbA1c values. Levels of patient treatment self-management and disease knowledge were assessed using self-questionnaires.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Three hundred seventy-seven patients were analyzed. The medication possession ratio, already very high at baseline in the intervention (94.8%) and control (92.3%) groups, did not vary significantly after 6 months with no difference between the two groups. Significant decreases in HbA1c were observed in both groups at 6 months (p < 0.001) and 12 months (p < 0.01), with significantly greater changes from baseline in the intervention group than in the control group at 6 months (- 0.5% vs. - 0.2%, p = 0.0047) and 12 months (- 0.6% vs. - 0.2%, p = 0.0057). Patients in the intervention group showed greater improvement in their ability to self-manage treatment (+ 4.86 vs. + 1.58, p = 0.0014) and in the extent of their knowledge about diabetes (+ 0.6 vs. + 0.2, p < 0.01) at 6 months versus baseline compared with the control group.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Tailored information provided by the pharmacist to patients with type 2 diabetes did not significantly improve the already high adherence rates, but was associated with a significant decrease in HbA1c and an improvement of patient knowledge about diabetes.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>TRIAL REGISTRATION</b>
</p>
<p>ISRCTN33776525.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>FUNDING</b>
</p>
<p>MSD France.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31049873</PMID>
<DateCompleted><Year>2020</Year>
<Month>04</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>36</Volume>
<Issue>6</Issue>
<PubDate><Year>2019</Year>
<Month>06</Month>
</PubDate>
</JournalIssue>
<Title>Advances in therapy</Title>
<ISOAbbreviation>Adv Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.</ArticleTitle>
<Pagination><MedlinePgn>1291-1303</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-019-00957-y</ELocationID>
<Abstract><AbstractText Label="INTRODUCTION">Low-quality communication between patients and care providers and limited patient knowledge of the disease and the therapy are important factors associated with poor glycemic control in patients with type 2 diabetes. We conducted a multicenter study to determine whether structured and tailored information delivered by pharmacists to type 2 diabetic patients could improve patient treatment adherence, hemoglobin A1c (HbA1c) levels and knowledge about diabetes.</AbstractText>
<AbstractText Label="METHODS">One hundred seventy-four pharmacies were randomized to deliver an educational program on diet, drug treatment, disease and complications during three 30-min interviews over a 6-month period, or to provide no intervention, to type 2 diabetic patients treated with oral antidiabetic agents. Medication adherence was assessed by measuring the medication possession ratio and diabetes control by collecting HbA1c values. Levels of patient treatment self-management and disease knowledge were assessed using self-questionnaires.</AbstractText>
<AbstractText Label="RESULTS">Three hundred seventy-seven patients were analyzed. The medication possession ratio, already very high at baseline in the intervention (94.8%) and control (92.3%) groups, did not vary significantly after 6 months with no difference between the two groups. Significant decreases in HbA1c were observed in both groups at 6 months (p < 0.001) and 12 months (p < 0.01), with significantly greater changes from baseline in the intervention group than in the control group at 6 months (- 0.5% vs. - 0.2%, p = 0.0047) and 12 months (- 0.6% vs. - 0.2%, p = 0.0057). Patients in the intervention group showed greater improvement in their ability to self-manage treatment (+ 4.86 vs. + 1.58, p = 0.0014) and in the extent of their knowledge about diabetes (+ 0.6 vs. + 0.2, p < 0.01) at 6 months versus baseline compared with the control group.</AbstractText>
<AbstractText Label="CONCLUSION">Tailored information provided by the pharmacist to patients with type 2 diabetes did not significantly improve the already high adherence rates, but was associated with a significant decrease in HbA1c and an improvement of patient knowledge about diabetes.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION">ISRCTN33776525.</AbstractText>
<AbstractText Label="FUNDING">MSD France.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michiels</LastName>
<ForeName>Yves</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bugnon</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chicoye</LastName>
<ForeName>Annie</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Institut d'Études Politiques de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dejager</LastName>
<ForeName>Sylvie</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>MSD France, Courbevoie, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moisan</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Diabetology, Pitie Salpetrière, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Allaert</LastName>
<ForeName>François-André</ForeName>
<Initials>FA</Initials>
<AffiliationInfo><Affiliation>Evaluation Chair BSB-Cenbiotech, Dijon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hunault</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>MSD France, Courbevoie, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Romengas</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Observia Group, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Méchin</LastName>
<ForeName>Hubert</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Observia Group, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vergès</LastName>
<ForeName>Bruno</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">0000-0001-8957-629X</Identifier>
<AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology and Metabolic Diseases, CHU Dijon, Dijon, France. bruno.verges@chu-dijon.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName>
<AccessionNumberList><AccessionNumber>ISRCTN33776525</AccessionNumber>
</AccessionNumberList>
</DataBank>
<DataBank><DataBankName>figshare</DataBankName>
<AccessionNumberList><AccessionNumber>10.6084/m9.figshare.7964879</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>05</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Adv Ther</MedlineTA>
<NlmUniqueID>8611864</NlmUniqueID>
<ISSNLinking>0741-238X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>T</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006943" MajorTopicYN="N">Hyperglycemia</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010595" MajorTopicYN="N">Pharmacists</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010817" MajorTopicYN="Y">Physician-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Disease knowledge</Keyword>
<Keyword MajorTopicYN="Y">Glucose control</Keyword>
<Keyword MajorTopicYN="Y">Patient information</Keyword>
<Keyword MajorTopicYN="Y">Pharmacist</Keyword>
<Keyword MajorTopicYN="Y">Type 2 diabetes</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>03</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>5</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31049873</ArticleId>
<ArticleId IdType="doi">10.1007/s12325-019-00957-y</ArticleId>
<ArticleId IdType="pii">10.1007/s12325-019-00957-y</ArticleId>
<ArticleId IdType="pmc">PMC6824455</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>AIDS Patient Care STDS. 2014 Dec;28(12):622-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25396706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Endocr Pract. 2016 Jan;22(1):84-113</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26731084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Patient Prefer Adherence. 2016 Aug 16;10:1573-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27574406</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2006 Dec 6;296(21):2563-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17101639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Res Ther. 2004 Apr;42(4):409-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14998735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Manag Care Spec Pharm. 2016 May;22(5):493-515</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27123912</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Health Econ. 2018 Mar;19(2):189-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28190188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2017 Nov;40(11):1425-1432</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28801473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Manag Care. 2012 Apr;18(3 Suppl):S43-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22558941</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Saudi Pharm J. 2016 Jan;24(1):40-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26903767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab. 2013 May;39(3):250-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23523643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Pharmacother. 2004 Sep;38(9):1357-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15238621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Patient Educ Couns. 2016 Jun;99(6):926-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26658704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Dermatol. 2014 Aug;150(8):813-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24898730</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Pharm Ther. 2011 Oct;36(5):602-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21143256</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Endocrinol (Oxf). 2014 Jan;80(1):47-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23194193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Health Serv Res. 2014 Nov 13;14:533</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25391694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2009 Jan;32(1):19-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18852334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Pharmacother. 2011 Feb;45(2):145-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21304027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Obes Metab. 2018 Jan;20(1):185-194</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28730750</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chronic Illn. 2014 Dec;10(4):291-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24567193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Res Opin. 2014 Jul;30(7):1309-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24502771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2011 Jan;34(1):20-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20929988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoepidemiol Drug Saf. 2004 Sep;13(9):591-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15362081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Jul 18;369(3):287-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23863067</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Educ. 2011 Nov-Dec;37(6):801-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22021025</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes. 2016 Jan;8(1):76-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25565383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Intern Med. 2003 Aug;18(8):624-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12911644</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Ther. 2014 Jul-Aug;21(4):234-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23344108</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):57-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21335480</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2018 May;41(5):929-932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29678864</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Health Educ Behav. 2010 Dec;37(6):849-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21076128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm World Sci. 2006 Apr;28(2):65-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16791717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Swiss Med Wkly. 2002 Jul 13;132(27-28):379-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12428192</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Pharmacother. 2017 Apr;18(5):503-515</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28276972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2017 Nov;40(11):1469-1478</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28801475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Manag Care Spec Pharm. 2017 May;23(5):573-582</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28448779</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab. 2003 Feb;29(1):79-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12629452</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
<li>Suisse</li>
</country>
<region><li>Bourgogne</li>
<li>Bourgogne-Franche-Comté</li>
<li>Canton de Vaud</li>
<li>Île-de-France</li>
</region>
<settlement><li>Dijon</li>
<li>Lausanne</li>
<li>Paris</li>
</settlement>
<orgName><li>Université de Genève</li>
</orgName>
</list>
<tree><country name="Suisse"><region name="Canton de Vaud"><name sortKey="Michiels, Yves" sort="Michiels, Yves" uniqKey="Michiels Y" first="Yves" last="Michiels">Yves Michiels</name>
</region>
<name sortKey="Bugnon, Olivier" sort="Bugnon, Olivier" uniqKey="Bugnon O" first="Olivier" last="Bugnon">Olivier Bugnon</name>
<name sortKey="Bugnon, Olivier" sort="Bugnon, Olivier" uniqKey="Bugnon O" first="Olivier" last="Bugnon">Olivier Bugnon</name>
<name sortKey="Michiels, Yves" sort="Michiels, Yves" uniqKey="Michiels Y" first="Yves" last="Michiels">Yves Michiels</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Chicoye, Annie" sort="Chicoye, Annie" uniqKey="Chicoye A" first="Annie" last="Chicoye">Annie Chicoye</name>
</region>
<name sortKey="Allaert, Francois Andre" sort="Allaert, Francois Andre" uniqKey="Allaert F" first="François-André" last="Allaert">François-André Allaert</name>
<name sortKey="Dejager, Sylvie" sort="Dejager, Sylvie" uniqKey="Dejager S" first="Sylvie" last="Dejager">Sylvie Dejager</name>
<name sortKey="Hunault, Catherine" sort="Hunault, Catherine" uniqKey="Hunault C" first="Catherine" last="Hunault">Catherine Hunault</name>
<name sortKey="Mechin, Hubert" sort="Mechin, Hubert" uniqKey="Mechin H" first="Hubert" last="Méchin">Hubert Méchin</name>
<name sortKey="Moisan, Christine" sort="Moisan, Christine" uniqKey="Moisan C" first="Christine" last="Moisan">Christine Moisan</name>
<name sortKey="Romengas, Laura" sort="Romengas, Laura" uniqKey="Romengas L" first="Laura" last="Romengas">Laura Romengas</name>
<name sortKey="Verges, Bruno" sort="Verges, Bruno" uniqKey="Verges B" first="Bruno" last="Vergès">Bruno Vergès</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000542 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000542 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    AutomedicationFrancoV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31049873
   |texte=   Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31049873" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AutomedicationFrancoV1

This area was generated with Dilib version V0.6.38.
Data generation: Mon Mar 15 15:24:36 2021. Site generation: Mon Mar 15 15:32:03 2021

	Serveur d'exploration sur l'automédication dans le monde francophone
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'automédication dans le monde francophone

Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.

Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki